SALOME UGWU: Open Payments
NPI 1487402897 · CLIFTON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$648 in 17 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $174 · 2025 $648
Food & beverage: $425Education: $223
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 5 | $267 |
| ABBVIE INC. | 3 | $152 |
| Janssen Pharmaceuticals, Inc | 1 | $56 |
| Otsuka America Pharmaceutical, Inc. | 1 | $46 |
| Vanda Pharmaceuticals Inc. | 2 | $34 |
| Gilead Sciences, Inc. | 1 | $23 |
| Neurocrine BioSciences, Inc. | 1 | $20 |
| Indivior Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| Alkermes, Inc. | 1 | $15 |
Products named: VRAYLAR, REXULTI, INVEGA SUSTENNA, AUSTEDO XR, HETLIOZ, INGREZZA, SUBLOCADE, ARISTADA.
Industry payments across NJ — which companies pay providers there.
